You are here: All Products  > Hepalink Acquires China Rights to Resverlogix CV Drug for $27.4 Million

Hepalink Acquires China Rights to Resverlogix CV Drug for $27.4 Million

Price: $5.00
Available
Get instant access to this article for unlimited viewing and/or downloading for seven days.

Back to products